Pyxis Oncology, INC 10-Q quarterly reports

Pyxis Oncology reports continued operating losses and substantial R&D expenses, raising concerns about its ability to continue as a going concern despite a recent private placement.

Pyxis Oncology filed its Q1 2026 Form 10-Q, detailing a net loss of $23.3 million and highlighting progress in its MICVO clinical development programs.

Pyxis Oncology reported increased net losses and a going concern warning, while advancing its lead oncology candidate, micvotabart pelidotin, with positive preliminary HNSCC clinical data and Fast Track Designation.

Pyxis Oncology reported increased losses in Q2 2025 but highlighted positive clinical data and Fast Track designation for its lead oncology candidate, micvotabart pelidotin.

Pyxis Oncology's Q1 2025 results show a net loss of $21.2 million, with strategic focus shifting towards advancing micvotabart pelidotin, particularly in R/M HNSCC.

Pyxis Oncology reports a net loss of $41.8 million for the nine months ended September 30, 2024, while highlighting progress in its clinical programs for PYX-201 and PYX-106.

Pyxis Oncology reports a net loss of $20.6 million for the six months ended June 30, 2024, alongside updates on its clinical programs and financial position.

Pyxis Oncology reports a net loss of $3.3 million for the first quarter of 2024, driven by increased research and development expenses, but offset by a one-time revenue gain from the sale of royalty rights.